Search
Vosoritide
go.drugbank.com/drugs/DB11928ApprovedInvestigational[L39229] It was approved for use under the brand name Voxzogo (BioMarin Pharmaceutical Inc.) in the EU in August 2021 and the US in November 2021,[L39245,L39241] becoming the first pharmacological intervention … [A242273] While the remarkably short half-life of endogenous CNP - 2 to 3 minutes due to its rapid degradation by endopeptidases - makes it ineffective as a therapeutic intervention,[A242273] the development
Amsilarotene
go.drugbank.com/drugs/DB21085InvestigationalAmsilarotene is under investigation in clinical trial NCT00687596 (Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy … Amsilarotene has a monoisotopic molecular weight of 385.15 Da.
Aflibercept
go.drugbank.com/drugs/DB08885ApprovedInvestigational[L47976] An aflibercept biosimilar, Yesafili, was approved for use in the EU in September 2023. … [A261281,A261286] Due to the 2 fused VEGFR, aflibercept has a higher affinity to the cognate ligands than the endogenous individual receptor.
Products: EYLEA SOLUTION FOR INJECTION IN VIAL 2MG, EYLEA 40MG/ML SOLUTION FOR INJECTION IN VIALBalsam of Peru
go.drugbank.com/drugs/DB11482ApprovedNutraceuticalVet approved[F117] Under the FDA, balsam of Peru is considered as an inactive ingredient to be used for approved drug products[L2878] as well as an approved food additive under the categorization of generally recognized … [L2879] By Health Canada, the balsam of Peru is approved by the use of over-the-counter combination products and it is currently approved in veterinary products.
Mixtures: Arnica De LA AbuelaCategories: Compounds used in a research, industrial, or household settingMagnesium cation
go.drugbank.com/drugs/DB01378ApprovedInvestigationalNutraceuticalWithdrawnMagnesium hydroxide is used primarily in "Milk of Magnesia", a white aqueous, mildly alkaline suspension of magnesium hydroxide formulated at about 8%w/v. … draw fluids from the body and to retain those already within the lumen of the intestine, serving to distend the bowel, thus stimulating nerves within the colon wall, inducing peristalsis and resulting in
Mixtures: KALSİMAG-D3 1000 MG/300 MG/880 IU EFERVESAN GRANÜL, 30 ADET, KALSİMAG-D3 1000 MG/300 MG/880 IU EFERVESAN GRANÜL, 40 ADETFostamatinib
go.drugbank.com/drugs/DB12010ApprovedInvestigationalIt was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, L52150]. Fostamatinib has also been granted orphan drug status by the FDA [L2644]. … Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK
Promethazine
go.drugbank.com/drugs/DB01069ApprovedInvestigationalPromethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946.
Mixtures: COPHADYL-E COUGH LINCTUS, Promethazine DMCategories: Dopamine D2 Receptor AntagonistsLincomycin
go.drugbank.com/drugs/DB01627ApprovedInvestigationalVet approvedin use. … [A190621] Clinical use of lincomycin has largely been superseded by its semisynthetic derivative [clindamycin] due to its higher efficacy and a wider range of susceptible organisms, though lincomycin remains
Interferon alfa-2b
go.drugbank.com/drugs/DB00105ApprovedInvestigationalInterferon alpha 2b (human leukocyte clone hif-sn 206 protein moiety reduced). A type I interferon consisting of 165 amino acid residues with arginine in position 23. … It is used extensively as an antiviral or antineoplastic agent.
Mixtures: Rebetron Solution (albumin (human) Free) (18 Miu Multi-dose Pen / 200mg Capsules), Rebetron Ready To Use Solution (albumin(human)free) (6000000 Iu/ml and 200mg Capsules)Products: VIRAFERON INYECTABLE 3 MILLONES IU, INTRON A MULTIDOSE PEN 30 miu/penDiazoxide
go.drugbank.com/drugs/DB01119ApprovedInvestigational[A190372] Diazoxide is commonly used in the treatment of hyperinsulinaemic hypoglycemia due to its ability to inhibit insulin release. … [A255647,L44612] In March 2025, an extended-release formulation of diazoxide choline was approved by the FDA for the treatment of hyperphagia in patients with Prader-Willi syndrome, becoming the first
Categories: Arteriolar Smooth Muscle, Agents Acting On